OMER · Omeros Corporation

Omeros Corporation's FY2025 financial results show a net loss of -$3.4M under GAAP, reflecting the company's position as a clinical-stage biopharmaceutical firm investing in product development amid strategic shifts. This net income figure arises from core operations, where research, development, and administrative expenses continue to drive losses typical for biotech companies advancing pipelines without near-term commercial offsets.

Cash flow dynamics underscore persistent operational funding needs. Net cash provided by operating activities totaled -$116.1M for the fiscal year ended December 31, 2025. This burn stems from the nature of biotech operations, including timing of payments and receipts, as well as non-cash adjustments that do not generate immediate liquidity. Capital expenditures remained modest at $65K, resulting in free cash flow of -$116.2M. Investors should note that such cash usage supports ongoing clinical and preclinical efforts, where delays in trials—as highlighted in management commentary—could further elevate costs and complicate capital raises.

Overall, these results position Omeros with enhanced liquidity from partnerships to navigate biotech risks, focusing investor attention on execution amid cash discipline. The -$116.2M free cash flow signals the imperative for prudent resource allocation to extend runway through key milestones.